Package Insert: Information for the User

Vildagliptin Viatris 50 mg Tablets EFG

Read this package insert carefully before starting to take this medicine, as it contains important information for you.

-Keep this package insert, as you may need to read it again.

-If you have any questions, consult your doctor or pharmacist.

-This medicine has been prescribed only for you and should not be given to others, even if they have the same symptoms as you, as it may harm them.

-If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package insert. See section 4.

1. What is Vildagliptin Viatris and what is it used for

2. What you need to know before starting to take Vildagliptin Viatris

3. How to take Vildagliptin Viatris

4. Possible side effects

5. Storage of Vildagliptin Viatris

6. Contents of the pack and additional information

The active ingredient vildagliptin belongs to a group of medications called “oral antidiabetics”.

Vildagliptin is used to treat adult patients with type 2 diabetes when diabetes cannot be controlled solely with diet and exercise. It helps control blood sugar levels. Your doctor will prescribe vildagliptin only or in combination with other antidiabetic medications you are already taking, if these are not effective enough to control diabetes.

Type 2 diabetes appears if the body does not produce enough insulin or if the insulin produced does not work properly.It can also appear if the body produces too much glucagon.

Insulin is a substance that helps reduce blood sugar levels, especially after meals. Glucagon is a substance that promotes sugar production by the liver and causes blood sugar levels to increase. Both substances are produced in the pancreas.

How vildagliptin works

Vildagliptin stimulates the pancreas to produce more insulin and less glucagon. This helps control blood sugar levels. This medication has been shown to reduce blood sugar, which will help prevent diabetes complications.

Although you start taking this medication for your diabetes, it is essential that you continue with the diet and/or exercise that have been recommended.

Do not take this medication

-if you are allergic to vildagliptin or any of the other ingredients in this medication (listed in section 6). If you think you may be allergic to vildagliptin or any other ingredient in this medication, do not take this medication and consult your doctor.

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting to take this medication

• if you have type 1 diabetes (i.e., your body does not produce insulin) or if you have a condition called diabetic ketoacidosis,
• if you are taking a diabetes medication known as a sulfonylurea (your doctor may want to reduce your sulfonylurea dose when taken with vildagliptin to avoid low blood sugar [hypoglycemia]),
• if you have moderate or severe kidney disease (you will need to take a lower dose of vildagliptin),
• if you are undergoing dialysis,
• if you have liver disease,
• if you have heart failure,
• if you have or have had pancreatitis.

If you have previously taken vildagliptin but had to stop due to liver disease, do not take this medication.

Skin lesions are common complications of diabetes. Follow your doctor's or nurse's recommendations for skin and foot care, paying special attention to the appearance of blisters or ulcers while taking vildagliptin. If this occurs, you should consult your doctor as soon as possible.

Liver function tests should be performed before starting treatment with vildagliptin, at three-month intervals during the first year, and periodically thereafter.This is done to detect as soon as possible any signs indicating an increase in liver enzymes (transaminases).

Children and adolescents

The administration of vildagliptin is not recommended in children and adolescents under 18 years.

Other medications and Vildagliptin Viatris

Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.

Your doctor may change your vildagliptin dose if you are taking other medications such as:

• thiazides or other diuretics (also called urine medications),
• corticosteroids (usually used to treat inflammation),
• thyroid medications,
• certain medications that affect the nervous system.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

You should not use vildagliptin during pregnancy. It is unknown whether vildagliptin passes into breast milk. Do not take vildagliptin if you are breastfeeding or plan to breastfeed.

Driving and operating machinery

If you feel dizzy while taking vildagliptin, do not drive or operate tools or machinery.

Your ability to concentrate and react may be affected due to symptoms caused by hypoglycemia or hyperglycemia, such as blurred vision. This can be hazardous in situations where these skills are important (e.g., driving or using machinery). Therefore, consult your doctor if it is recommended to drive or use machinery.

Vildagliptin Viatris contains lactose

If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.

Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

What amount to take and when

The dose of vildagliptin that you should take varies depending on your condition. Your doctor will tell you exactly how many tablets of vildagliptin you should take. The maximum daily dose is 100 mg.

The usual dose of vildagliptin is:

• 50 mg once a day in the morning, if you are taking vildagliptin with another medication known as a sulfonylurea.

• 100 mg per day in two doses (50 mg in the morning and 50 mg in the evening) if you are taking vildagliptin alone, with another medication called metformin or a glitazone, with a combination of metformin and a sulfonylurea, or with insulin.

• 50 mg per day in the morning if you have moderate to severe kidney disease or if you are undergoing dialysis.

How to take Vildagliptin Viatris

• Swallow the tablet whole with a little water.

Duration of treatment with Vildagliptin Viatris

• Take vildagliptin every day as your doctor tells you to. You may need to continue this treatment for a long time.
• Your doctor will perform regular check-ups to ensure that the treatment is having the desired effect.

If you take more Vildagliptin Viatris than you should

If you have taken too many tablets of vildagliptin, or if someone else has taken your medication, consult your doctor immediately , or call the Toxicology Information Service, phone 91 562 04 20 . You may need medical attention. If you need to visit a doctor or go to the nearest hospital, bring the packaging with you.

If you forget to take Vildagliptin Viatris

If you forget to take a dose of this medication, take it as soon as you remember. Then take the next dose at your usual time. If it is almost time for your next dose, skip the missed dose. Do not take a double dose to make up for the missed doses.

If you interrupt treatment with Vildagliptin Viatris

Do not stop taking vildagliptin unless your doctor tells you to. If you have doubts about the duration of treatment with vildagliptin, consult your doctor.

Like all medicines, this medicine can cause side effects, although not everyone will experience them.

Some symptoms require immediate medical attention

You should stop taking vildagliptin and seek medical attention immediately if you experience any of the following side effects:

• Angioedema (rare: may affect up to 1 in 1,000 people): symptoms that include swelling of the face, tongue, or throat, difficulty swallowing, difficulty breathing, sudden appearance of hives or urticaria, which may be indicative of a reaction called “angioedema”,
• Liver disease (hepatitis) (unknown frequency): symptoms that include yellowing of the skin and eyes, nausea, loss of appetite, or dark-colored urine, which may be indicative of liver disease (hepatitis).
• Pancreatitis (inflammation of the pancreas) (rare: may affect up to 1 in 1,000 people): symptoms that include intense and persistent pain in the abdomen (stomach area), which may radiate to your back, as well as nausea and vomiting.

Other side effects

Some patients experienced the following side effects while taking vildagliptin:

• Very common (may affect more than 1 in 10 people): sore throat, nasal congestion, fever.
• Common (may affect up to 1 in 10 people): itchy rash, tremor, headache, dizziness, muscle pain, joint pain, constipation, swollen hands, ankles, or feet (edema), excessive sweating, vomiting, stomach pain and abdominal pain, diarrhea, heartburn, nausea (discomfort), blurred vision.
• Uncommon (may affect up to 1 in 100 people): weight gain, chills, weakness, sexual dysfunction, low blood glucose levels, flatulence.
• Rare (may affect up to 1 in 1,000 people): pancreatitis (inflammation of the pancreas).

Since the marketing of this product, the following side effects have also been reported:

• Unknown frequency (cannot be estimated from available data): localized skin peeling or blisters, inflammation of blood vessels (vasculitis) that may cause skin eruptions or pinpoint, flat, red, and rounded spots under the skin's surface or bruises.

Reporting side effects

If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the blister and on the packaging after “CAD” or “EXP”. The expiration date is the last day of the month indicated.

This medication does not require special storage conditions.

Do not use vildagliptina if you observe that the packaging is damaged or shows signs of manipulation.

Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.

Composition of Vildagliptin Viatris

• The active ingredient is vildagliptin.

Each tablet contains 50 mg of vildagliptin.

• The other components are lactose (see section 2, “Before taking/using Vildagliptin Viatris”), microcrystalline cellulose, pregelatinized maize starch, and magnesium stearate.

Appearance of the product and contents of the package

Vildagliptin Viatris 50 mg tablets are round, white to off-white, flat tablets with “VLD” on one face and plain on the other.

Vildagliptin Viatris 50 mg tablets are available in packages containing 7, 14, 28, 30, 56, 60, 90, 112, 180, or 336 tablets and in multiple packs formed by 3 packages, each containing 112 tablets.

Only some package sizes may be marketed.

Marketing Authorization Holder

Viatris Limited

Damastown Industrial Park

Mulhuddart, Dublin 15

Dublin

Ireland

Responsible for manufacturing

Adipharm EAD

130 ‘Simeonovsko shosse’ Blvd.,

1700 Sofia,

Bulgaria

or

Combino Pharm (Malta) Ltd.

HF60, Hal Far Industrial Estate

BBG3000,

Malta

or

Genepharm S.A.

18thkm Marathonos Avenue

15351 Pallini Attiki

Greece

For more information about this medication, please contact the local representative of the marketing authorization holder:

Viatris Pharmaceuticals, S.L.U.

C/ General Aranaz, 86

28027 – Madrid

Spain

This medication is authorized in the member states of the European Economic Area with the following names:

DenmarkVildagliptin Mylan

SpainVildagliptina Viatris 50 mg tablets EFG

FranceVildagliptine Mylan 50 mg, tablet

FinlandVildagliptin Mylan

ItalyVildagliptin Mylan

NorwayVildagliptin Mylan

PortugalVildagliptina Mylan

Last review date of this leaflet: 07/2023

For detailed information about this medication, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/